MicrodosingLSDPsilocybin

Motives and side-effects of microdosing with psychedelics among users

Surveying 1,116 psychedelic users, the study found most microdosed with LSD or psilocybin—typically 2–4 times weekly—primarily to enhance performance and commonly experienced acute psychological side‑effects while under the influence, with many stopping because they perceived no benefit. The authors conclude that placebo‑controlled experimental studies are needed to quantify any performance enhancement and assess longer‑term harms.

Authors

  • Patrick Dolder
  • Kim Kuypers
  • Nathalie Mason

Published

International Journal of Neuropsychopharmacology
individual Study

Abstract

Background

Microdosing with psychedelics has gained considerable media attention where it is portrayed as a performance enhancer, especially popular on the work floor. While reports are in general positive, scientific evidence about potential negative effects is lacking aside from the prevalence and motives for use. The present study addressed this gap by surveying psychedelic users about their experience with microdosing including their dosing schedule, motivation, and potential experienced negative effects.

Methods

An online questionnaire was launched on several websites and fora between March and July 2018. Respondents who had consented, were 18 years of age or older, and had experience with microdosing were included in the analyses.

Results

In total, 1116 of the respondents were either currently microdosing (79.5%) or microdosed in the past (20.5%). Lysergic acid diethylamide (10 mcg) and psilocybin (0.5 g) were the most commonly used psychedelics with a microdosing frequency between 2 and 4 times per week. The majority of users, however, were oblivious about the consumed dose. Performance enhancement was the main motive to microdose (37%). The most reported negative effects were of psychological nature and occurred acutely while under the influence.

Conclusion

In line with media reports and anecdotes, the majority of our respondents microdosed to enhance performance. Negative effects occurred mostly acutely after substance consumption. However, the main reason to have stopped microdosing was that it was not effective. Future experimental placebo-controlled studies are needed to test whether performance enhancement can be quantified and to assess potential negative effects after longer term microdosing.

Available with Blossom Pro

Research Summary of 'Motives and side-effects of microdosing with psychedelics among users'

Introduction

Microdosing, defined as repeatedly taking a low dose of psychedelics such as LSD or psilocybin without inducing overt perceptual changes, has received substantial media attention as a putative performance enhancer. Earlier research on low doses exists but is limited, and key features of current microdosing practice — including exact doses, schedules, prevalence across substances and workplaces, motives, and possible adverse effects — remain incompletely characterised. Small placebo-controlled laboratory studies have so far produced mixed or null findings on some subjective outcomes, and anecdotal reports dominate public discourse. Hutten and colleagues set out to address this gap by conducting an online questionnaire survey of people with psychedelic experience to quantify lifetime psychedelic use, microdosing practices (dose, frequency, route and how schedules were obtained), motives for microdosing, prevalence of microdosing at work, and the occurrence and timing of negative effects. The stated aim was descriptive: to provide detailed user-reported data that can inform future experimental and clinical investigations of efficacy and safety of microdosing.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (9)

Papers cited by this study that are also in Blossom

Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences

Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)

Psychedelics and the essential importance of context

Carhart-Harris, R. L., Roseman, L., Haijen, E. C. H. M. et al. · Journal of Psychopharmacology (2018)

Psilocin and ketamine microdosing: effects of subchronic intermittent microdoses in the elevated plus-maze in male Wistar rats

Horsley, R. R., Páleníček, T., Kolin, J. et al. · Behavioural Pharmacology (2018)

Powerful substances in tiny amounts An interview study of psychedelic microdosing

Johnstad, P. G. · Nordic Studies on Alcohol and Drugs (2018)

121 cited
Modern clinical research on LSD

Liechti, M. E. · Neuropsychopharmacology (2017)

A systematic study of microdosing psychedelics

Polito, V., Stevenson, R. J. · PLOS ONE (2019)

197 cited
Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting

Prochazkova, L., Lippelt, D. P., Colzato, L. S. et al. · Psychopharmacology (2018)

The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)

The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial

Yanakieva, S., Polychroni, N., Family, N. et al. · Psychopharmacology (2018)

Cited By (32)

Papers in Blossom that reference this study

What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial

Joy Donegan, C., Daldegan-Bueno, D., Sumner, R. L. et al. · Therapeutic Advances in Psychopharmacology (2025)

Global Trends in Psychedelic Microdosing: Demographics, Substance Testing Behavior, and Patterns of Use

Syed, O. A., Petranker, R., Fewster, E. C. et al. · Journal of Psychoactive Drugs (2024)

Neural complexity is increased after low doses of LSD, but not moderate to high doses of oral THC or methamphetamine

Murray, C., Frohlich, J, Haggarty, C. J., Tare, I. et al. · Neuropsychopharmacology (2024)

The risk of chronic psychedelic and MDMA microdosing for valvular heart disease

Tagen, M., Mantuani, D., Van Heerden, L. et al. · Journal of Psychopharmacology (2023)

10 cited
The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study

Kinderlehrer, D. A. · International Medical Case Reports Journal (2023)

Show all 32 papers
Microdosing psychedelics - Does it have an impact on emodiversity?

Pop, I., Dinkelacker, J. · Journal of Psychedelic Studies (2023)

Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study

Cavanna, F., Muller, S., de la Fuente, L. A. et al. · Translational Psychiatry (2022)

90 cited
Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study

Hartong, V., van Emmerik, A. · Journal of Psychoactive Drugs (2022)

Natural language signatures of psilocybin microdosing

Sanz, C., Cavanna, F., Muller, S. et al. · Psychopharmacology (2022)

11 cited
Microdosing with psychedelics to self-medicate for ADHD symptoms in adults: A prospective naturalistic study

Haijen, E., Hurks, P. P. M., Kuypers, K. P. C. · Neuroscience Applied (2022)

Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing

Kaertner, L. S., Steinborn, M. B., Kettner, H. et al. · Scientific Reports (2021)

112 cited
Investigation of the Structure-Activity Relationships of Psilocybin Analogues

Klein, A. K., Chatha, M., Laskowski, L. J. et al. · ACS Pharmacology and Translational Science (2020)

Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study

Hutten, N. R. P. W., Mason, N. L., Dolder, P. C. et al. · European Neuropsychopharmacology (2020)

95 cited
Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants

Zhang, D. Z., Holze, F., Liechti, M. E. et al. · Clinical Pharmacology and Therapeutics (2020)

49 cited
The therapeutic potential of microdosing psychedelics in depression

Kuypers, K. P. C. · Therapeutic Advances in Psychopharmacology (2020)

Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.

Rosenbaum, D., Weissman, C. R., Anderson, T. et al. · Journal of Psychopharmacology (2020)

55 cited
Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers

Hutten, N. P. W., Mason, N. L., Dolder, P. C. et al. · Frontiers in Psychiatry (2019)

Accounting for Microdosing Classic Psychedelics

Beaton, B., Copes, H., Webb, M. et al. · Journal of Drug Issues (2019)

13 cited

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.